CDK1基因在肺动脉高压中表达和临床意义的生物信息学分析

秦雨晗; 乔勇; 鄢高亮; 王栋; 汤成春

doi:10.13201/j.issn.1001-1439.2021.07.012

CDK1基因在肺动脉高压中表达和临床意义的生物信息学分析

- 1. 东南大学医学院(南京, 210009);
- 2. 东南大学附属中大医院心内科
基金项目:
国家自然科学基金面上项目(No:81970237

81600227)

详细信息

通讯作者: 汤成春,E-mail:tangchengchun@hotmail.com

中图分类号: R541.5

收稿日期: 2021-01-18

Bioinformatics analysis of CDK1 gene expression and clinical significance in pulmonary hypertension

- 1. School of Medicine, Southeast University, Nanjing, 210009, China;
- 2. Department of Cardiology, Zhongda Hospital, Southeast University

More Information

Corresponding author: TANG Chengchun, E-mail: tangchengchun@hotmail.com

Received Date: 18 January 2021

摘要

摘要: 目的:通过生物信息学的方法分析筛选肺动脉高压(PAH)的关键基因。方法:通过GEO数据库下载GSE113439和GSE144274。依次进行GO、KEGG及GSEA进行功能及通路富集分析。利用String及Cytoscape软件建立蛋白互作(PPI)网络,进一步通过MCODE、CentiScape和CytoHubba插件筛选核心基因。结果:GSE113439中有544个DEGs(上调462个,下调82个),主要参与DNA双链解螺旋、DNA修复、有丝分裂核分裂等生物学过程。GSE144274中有1121个DEGs(上调702个,下调509个),主要参与细胞分裂、有丝分裂姐妹染色单体分离、染色体分离等生物学过程。两组数据集的DEGs均显著富集在细胞周期信号通路。建立PPI网络后,根据MCODE和CentiScape插件筛选出关键作用模块,根据MCC算法选择关键候选基因,并最终筛选出CDK1为关键基因。结论:CDK1是PAH的关键基因,可能成为PAH潜在的治疗靶点。
- CDK1 /
- 关键基因 /
- 肺动脉高压 /
- 生物信息学 /
- GEO
Abstract: Objective: The present research aims to explore the hub gene of pulmonary arterial hypertension(PAH) through bioinformatic analysis.Methods: GSE113439 and GSE144274 were downloaded from GEO(gene expression omnibus) database. “Limma”in R package was used for selecting different expressed genes(DEGs). Gene Ontology(GO) enrichment, Kyoto Encyclopedia of Genes and Genomes(KEGG) pathway and Gene Set Enrichment Analysis(GSEA) were sequentially performed to pick out the functional and differentially expressed pathways enrichment analysis. Protein-protein interaction(PPI) network was constructed through online tool String and Cytoscape software. The plug-in including MCODE, CentiScape and CytoHubba were utilized for selection of hub genes of PAH.Results: The 544 different expressed genes(DEGs) in GSE113439(462 upregulated and 82 downregulated) were selected out and they were enriched in DNA duplex unwinding, DNA repair and mitotic nuclear division in biological process(BP). The 1211 DEGs(702 upregulated and 509 downregulated) were selected out in GSE144274, and the DEGs were enriched in cell division, mitotic sister chromatid segregation and chromosome segregation in terms of BP. Consistently, DEGs were both significantly differentially enriched in cell cycle pathway in both GSE113439 and GSE144274. PPI network of the 544 DEGs of GSE113439 were constructed and then module 1 were picked out according to Molecular Complex Detection(MCODE) and CentiScape plug-in of Cytoscape. Maximal Clique Centrality(MCC) method in CytoHubba plug-in were utilized for selection of candidate genes. PPI network was also established in GSE144724, then followed by MCC method to select out the top 15 candidate genes, eventually CDK1 was ultimately selected as Hub gene.Conclusion: CDK1 is a key gene of PAH and it might exert as a potential therapeutic target for PAH.
- CDK1 /
- hub gene /
- pulmonary hypertension /
- bioinformatics /
- GEO

HTML全文

参考文献(33)

[1]	McGoon MD,Benza RL,Escribano-Subias P,et al.Pulmonary arterial hypertension:epidemiology and registries[J].J Am Coll Cardiol,2013,62:D51-59.
[2]	Thenappan T,Ormiston ML,Ryan JJ,et al.Pulmonary arterial hypertension:pathogenesis and clinical management[J].BMJ,2018,360:5492.
[3]	Simonneau G,Montani D,Celermajer DS,et al.Haemodynamic definitions and updated clinical classification of pulmonary hypertension[J].Eur Respir J,2019,53(1):120.
[4]	饶洋洋,周红梅,李艺,等.肺动脉高压合并心律失常的研究进展[J].临床心血管病杂志,2020,36(6):577-580.
[5]	Vonk-Noordegraaf A,Haddad F,Chin KM,et al.Right heart adaptation to pulmonary arterial hypertension:physiology and pathobiology[J].J Am Coll Cardiol,2013,62(25 Suppl):D22-33.
[6]	Zhang R,Dai LZ,Xie WP,et al.Survival of Chinese patients with pulmonary arterial hypertension in the modern treatment era[J].Chest,2011,140(2):301-309.
[7]	Ling Y,Johnson MK,Kiely DG,et al.Changing demographics,epidemiology,and survival of incident pulmonary arterial hypertension:results from the pulmonary hypertension registry of the United Kingdom and Ireland[J].Am J Respir Crit Care Med,2012,186(8):790-796.
[8]	Shen H,Zhang J,Wang C,et al.MDM2-mediated ubiquitination of angiotensin-converting enzyme 2 contributes to the development of pulmonary arterial hypertension[J].Circulation,2020,142(12):1190-1204.
[9]	Gräf S,Haimel M,Bleda M,et al.Identification of rare sequence variation underlying heritable pulmonary arterial hypertension[J].Nat Commun,2018,9(1):1416.
[10]	Rhodes CJ,Otero-Núňez P,Wharton J,et al.Whole-blood RNA profiles associated with pulmonary arterial hypertension and clinical outcome[J].Am J Respir Crit Care Med,2020,202(4):586-594.
[11]	Stearman RS,Bui QM,Speyer G,et al.Systems analysis of the human pulmonary arterial hypertension lung transcriptome[J].Am J Respir Cell Mol Biol,2019,60(6):637-649.
[12]	Barrett T,Suzek TO,Troup DB,et al.NCBI GEO:mining millions of expression profiles--database and tools[J].Nucleic Acids Res,2005,33:D562-566.
[13]	Zhou G,Soufan O,Ewald J,et al.NetworkAnalyst 3.0:a visual analytics platform for comprehensive gene expression profiling and meta-analysis[J].Nucleic Acids Res,2019,47(W1):W234-W241.
[14]	Ritchie ME,Phipson B,Wu D,et al.limma powers differential expression analyses for RNA-sequencing and microarray studies[J].Nucleic Acids Res,2015,43(7):e47.
[15]	Huang da W,Sherman BT,Lempicki RA.Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources[J].Nat Protoc,2009,4(1):44-57.
[16]	Ashburner M,Ball CA,Blake JA,et al.Gene ontology:tool for the unification of biology.The Gene Ontology Consortium[J].Nat Genet,2000,25(1):25-29.
[17]	Kanehisa M,Goto S.KEGG:kyoto encyclopedia of genes and genomes[J].Nucleic Acids Res,2000,28(1):27-30.
[18]	Shannon P,Markiel A,Ozier O,et al.Cytoscape:a software environment for integrated models of biomolecular interaction networks[J].Genome Res,2003,13(11):2498-504.
[19]	Hemnes AR,Humbert M.Pathobiology of pulmonary arterial hypertension:understanding the roads less travelled[J].Eur Respir Rev,2017,26(146):120.
[20]	Gaine S,McLaughlin V.Pulmonary arterial hypertension:tailoring treatment to risk in the current era[J].Eur Respir Rev,2017,26(146):100.
[21]	Farber HW,Miller DP,Poms AD,et al.Five-Year outcomes of patients enrolled in the REVEAL Registry[J].Chest,2015,148(4):1043-1054.
[22]	Zha LH,Zhou J,Li TZ,et al.NLRC3:A novel noninvasive biomarker for pulmonary hypertension diagnosis[J].Aging Dis,2018,9(5):843-851.
[23]	Frost A,Badesch D,Gibbs J,et al.Diagnosis of pulmonary hypertension[J].Eur Respir J,2019,53(1):100.
[24]	Galiè N,Humbert M,Vachiery JL,et al.2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension[J].Eur Heart J,2016,37:67-119.
[25]	Rosenkranz S,Preston IR.Right heart catheterisation:best practice and pitfalls in pulmonary hypertension[J].Eur Respir Rev,2015,24:642-652.
[26]	Gu M,Shao NY,Sa S,et al.Patient-specific iPSC-derived endothelial cells uncover pathways that protect against pulmonary hypertension in BMPR2 mutation carriers[J].Cell Stem Cell,2017,20(4):490-504.e5.
[27]	Morrell NW,Aldred MA,Chung WK,et al.Genetics and genomics of pulmonary arterial hypertension[J].Eur Respir J,2019,53:130.
[28]	Kan M,Shumyatcher M,Himes BE.Using omics approaches to understand pulmonary diseases[J].Respir Res,2017,18:149.
[29]	Zhu N,Pauciulo MW,Welch CL,et al.Novel risk genes and mechanisms implicated by exome sequencing of 2572 individuals with pulmonary arterial hypertension[J].Genome Med,2019,11(1):69.
[30]	Zhu TT,Zhang WF,Yin YL,et al.MicroRNA-140-5p targeting tumor necrosis factor-α prevents pulmonary arterial hypertension[J].J Cell Physiol,2019,234(6):9535-9550.
[31]	Malumbres M,Barbacid M.Cell cycle,CDKs and cancer:a changing paradigm[J].Nat Rev Cancer,2009,9(3):153-66.
[32]	Liu S,Yang Y,Jiang S,et al.Corrigendum:MiR-378a-5p regulates proliferation and migration in vascular smooth muscle cell by targeting CDK1[J].Front Genet,2019,10:193.
[33]	Weiss A,Neubauer MC,Yerabolu D,et al.Targeting cyclin-dependent kinases for the treatment of pulmonary arterial hypertension[J].Nat Commun,2019,10(1):2204.